Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Holding CHRS?
Track your performance easily
CHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.66 - $3.70
Previous Close$1.1
Volume1.20M
Average Volume (3M)2.66M
Market Cap
$124.43M
Enterprise Value$256.94M
Total Cash (Recent Filing)$97.69M
Total Debt (Recent Filing)$227.89M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Feb 27, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding115,213,407
10 Day Avg. Volume4,056,439
30 Day Avg. Volume2,655,171
Standard Deviation0.17
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.45
Price to Sales (P/S)0.31
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda6.89
Forecast
1Y Price Target
$7.67Price Target Upside610.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Coherus Biosciences News
PremiumCompany Announcements
Coherus BioSciences Reports Strong Q3 2024 Growth
PremiumCompany Announcements
Coherus Biosciences Manages UDENYCA Supply Interruption and Cost Reductions
Bulls Say, Bears Say
Bulls Say
EarningsUdenyca recorded $66.1M in 3Q24 revenues, above our estimate of $54M, driven by a 54% increase in demand for the Onbody injector and a higher overall net selling price.
Financial PerformanceNon-GAAP net loss was smaller than forecast, showing better financial performance.
Supply Chain ManagementCoherus added another CMO to produce Udenyca to avoid supply chain issues and expand productivity in the future.
Bears Say
Market PerformanceUdenyca's market share for Q3 was 28%, slightly decreasing from the previous quarter.
Pricing ChallengesPricing deterioration has worsened with -40% to -70% year-over-year declines in 1Q and 2Q of 2024 for Udenyca.
Supply Chain DisruptionCapacity constraints at its contract manufacturing organization (CMO) will result in a disruption of Udenyca supply.
---
Ownership Overview
1.31% Insiders
14.91% Mutual Funds
24.05% Other Institutional Investors
48.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.66 and its highest was $3.70 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Feb 27, 2025 which is in 97 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Nov 06, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.073.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -$0.31.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 115,213,410 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 13.889%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Graham Capital Management, L.P.. It holds Coherus Biosciences’s shares valued at 71K.
---
Coherus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (610.19% Upside)
$7.67 (610.19% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 289.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.50%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q3 2024
0:00 / 0:00
---
CHRS Stock 12 Month Forecast
Average Price Target
$7.67
▲(610.19% Upside)
Technical Analysis
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
3/24 ratings generated profit
1 Year Average Return
-34.95%
reiterated a buy rating 5 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.95% per trade.
---